Market Overview

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Intercept Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline


The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been commenced in
the United States District Court for the Southern District of New York
on behalf of purchasers of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) ("Intercept" or the "Company") securities during the period
between May 31, 2016 and September 20, 2017, inclusive (the "Class
Period"). Investors who wish to become proactively involved in the
litigation have until November 27, 2017 to seek appointment as lead

If you wish to choose counsel to represent you and the class, you must
apply to be appointed lead plaintiff and be selected by the Court. The
lead plaintiff will direct the litigation and participate in important
decisions including whether to accept a settlement for the class in the
action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in Intercept securities during
the Class Period. Members of the class will be represented by the lead
plaintiff and counsel chosen by the lead plaintiff. No class has yet
been certified in the above action.

The complaint accuses the defendants of violations of the Securities
Exchange Act of 1934 by virtue of the defendants' failure to disclose
during the Class Period that Ocaliva entailed undisclosed safety risks,
including death, to patients suffering from primary biliary cirrhosis

According to the complaint, following a September 12, 2017 letter
warning physicians against overdosing patients with Ocaliva and advising
them that the drug has been tied to liver injuries and death among
patients from PBC, and a September 21, 2017 safety announcement by the
Food and Drug Administration after reports of multiple deaths, the value
of Intercept shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in
Intercept securities purchased on or after May 31, 2016 and held through
the revelation of negative information during and/or at the end of the
Class Period and would like to learn more about this lawsuit and your
ability to participate as a lead plaintiff, without cost or obligation
to you, please visit our website at
You may also request more information by contacting Brower Piven either
by email at
or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating
securities and other class action cases and have been advocating for the
rights of shareholders since the 1980s. If you choose to retain counsel,
you may retain Brower Piven without financial obligation or cost to you,
or you may retain other counsel of your choice. You need take no action
at this time to be a member of the class.

View Comments and Join the Discussion!